Ireland
--:--IST
Recruiting Not applicable

LEXURE for Post-Stroke Aphasia

NCT07570264 · tracked via the Priya Life Science South Korea tracker
Sponsor
Nunaps Inc
Phase
Not applicable
Started
2026-04-16
Last updated
2026-05-14

Condition(s) studied

Aphasia

Investigational drug(s) / intervention(s)

LEXUREWorkbook

LEXURE: Participants will undergo a total of 50 training sessions, conducted 5 times per week for 10 weeks. Each session consists of five training tasks and takes approximately 30 minutes to complete..

Workbook: Participants will perform language training using a workbook. Training will be conducted 5 times per week for 10 weeks, with each session lasting approximately 30 minutes.

Study summary

This study evaluates the efficacy of digital language rehabilitation using LEXURE for the treatment of post-stroke aphasia. Half of participants will receive structured language training using the LEXURE application, while the other half will receive workbook-based language training as an active comparator.

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: 1. Diagnosed with hemorrhagic or ischemic stroke 2. At least 3 months have elapsed since stroke onset 3. History of aphasia resulting from stroke 4. Aphasia Quotient (AQ) score between 26 and 90 (inclusive) on the Korean version of the Western Aphasia Battery (K-WAB) or the Paradise Korean version of the Western Aphasia Battery-Revised (PK-WAB-R) 5. Adults aged 19 years or older 6. Native Korean speakers 7. Able to use the investigational device or perform workbook-based training without difficulty 8. Willing to participate voluntarily and provide written informed consent Exclusion Criteria: 1. Diagnosed with language impairment due to causes other than stroke (e.g., traumatic brain injury, brain tumor, or neurodegenerative disease) 2. History of language impairment due to developmental disorders 3. Currently receiving speech-language therapy or participating in another clinical trial related to language function 4. Currently receiving medication for severe psychiatric disorders (e.g., bipolar disorder, major depressive disorder, schizophrenia, alcohol dependence, or substance abuse) 5. Illiterate individuals 6. Individuals deemed unsuitable for participation in this study by the investigator 7. Severe cognitive impairment that would interfere with understanding or performing the study interventions

Primary outcome measure(s)

  • Change in K-WAB or PK-WAB-R Aphasia Quotient (AQ) Score — Baseline to Week 10
    Change in Aphasia Quotient (AQ) score from baseline to Week 10, measured using the Korean version of the Western Aphasia Battery (K-WAB) or the Paradise Korean version of the Western Aphasia Battery-Revised (PK-WAB-R). AQ scores range from 0 to 100, with higher scores indicating better language function. Assessments will be conducted by an independent, evaluator-blinded assessor.

Trial sites (12)

FacilityCityRegionStatus
Korea University Ansan Hospital Ansan Gyeonggi-do Not Yet Recruiting
Inje University Busan Paik Hospita Busan South Korea Recruiting
Hallym University Chuncheon Sacred Heart Hospital Chuncheon South Korea Recruiting
Kyungpook National University Hospital Daegu South Korea Not Yet Recruiting
Yeungnam University Medical Center Daegu South Korea Not Yet Recruiting
Keimyung University Dongsan Hospital Daegu South Korea Recruiting
Chonnam National University Hospital Gwangju South Korea Recruiting
Inje University Ilsan Paik Hospital Ilsan South Korea Recruiting
Jeonbuk National University Hospital Jeonju South Korea Not Yet Recruiting
Asan Medical Center Seoul South Korea Recruiting
Konkuk University Medical Center Seoul South Korea Recruiting
Ulsan University Hospital Ulsan South Korea Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07570264 on ClinicalTrials.gov ↗ ← All trials in South Korea